A couple of Wall Street analysts hit the brakes on stocks they previously championed, shifting their ratings to neutral territory on Tuesday.

Barclays analyst Benjamin Theurer downgraded Coca-Cola Femsa SAB de CV (KOF) from Overweight to Equal-Weight, though he maintained his $98 price target. That target still implies decent upside from Monday's closing price of $87.60, but apparently not enough to justify the bullish stance anymore. The Latin American beverage bottler and distributor—one of the world's largest Coca-Cola franchises—seems to have hit a ceiling in Theurer's view.

Meanwhile, Morgan Stanley analyst Tejas Savant downgraded 10x Genomics, Inc. (TXG) from Overweight to Equal-Weight, though he actually raised his price target from $17 to $20. That's an interesting combination: less enthusiastic about the stock relative to the market, but more optimistic about where it's headed. The genomics technology company closed at $18.08 on Monday, leaving some room to run if Savant's new target proves accurate.

These Equal-Weight ratings essentially mean the analysts see these stocks performing roughly in line with the broader market—not bad, not great, just kind of there. It's the financial equivalent of saying "it's fine" when someone asks how your day went.